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Elekta re-energizes rad iation therapy in Southwestern India
Amrita Institute of
Medical Sciences
and Research
Centre, Cochin
New Delhi
Mumbai
(Bombay)
Although AIMS is presently a
world-class medical center with
superspecialties in all major
departments, it opened with no
radiation therapy equipment at
all. However, under the spiritual
leadership of India’s Mata
Amritanandamayi (‘Amma,’ see
page 6), AIMS and Elekta
collaborated to make radiation
therapy services a reality. AIMS
began radiation treatments of
cancer patients in February 2004.
Until the inception of radiation
oncology services at AIMS in
2004, pain palliation was
typically the most that thousands
of cancer patients in Kerala could
hope for. “Nearby hospitals use
cobalt units almost exclusively, so
often the intent was palliative
even for potentially curable
diseases, due to the absence of
adequate treatment modalities,”
says AIMS Medical Director,
Prem Nair, M.D. “Today, with
two Precise Treatment SystemsTM
and a wealth of auxiliary
equipment, Kerala has a center
that aggressively pursues cure as
a philosophy. Following AIMS’s
lead, three additional centers in
Kerala and several in the rest of
India have placed orders for
linacs in 2004, a number of them
choosing Elekta.”        
AIMS started out small in
1998 with just 200 beds, but
since then has grown
dramatically, adding 800 beds
and a medical complex consisting
of a medical school, school of
nursing, school of pharmacy,
school of dentistry and several
specialty institutes under the
auspices of AIMS. Amrita
Medical School has super-
specialties in the departments of
cardiology, nephrology and
gastroenterology, with supporting
services in radiology and
pathology. A cancer center was in
embryonic stages in 1998, as
were plans to integrate a
department of radiation oncology
within the center. Final pre-
construction planning for the
radiation oncology department
began in 2000 and culminated in
equipment selection in 2002. 
Elekta presents key
advantages during
evaluation
Two of the main principals in
AIMS’s equipment evaluation
committee, Dr. Bhaskaran K.
Pillai, Ph.D., Chief Physicist and
Ron Gottsegen, Administrative
Director of AIMS (pictured left),
had virtually no experience with
Elekta equipment in 2000 when
evaluations began. In fact Dr.
Pillai had worked in the USA
with the treatment machines of a
major Elekta competitor for 33
years and went into the
evaluation with a strong
preference for this vendor. In
addition, another Elekta
competitor’s diagnostic imaging
equipment was already in place
at AIMS. The odds weren’t great
for a newcomer, but AIMS
brought in Elekta to ensure due
diligence. During the evaluation
process, Elekta advantages began
to mount, according to Dr. Pillai.
“Initially, I didn’t have a
specification for three photon
To meet the radiation therapy requirements of India’s population of 1.1 billion, the World Health
Organization has recommended a ratio of one linear accelerator (linac) for every one million people.
While there has been a large increase in the number of new linac orders in India in 2004, there are
only 85 linacs (installed/ordered) in the country. The state of Kerala on the southwest coast is home
to nearly 32 million people, the most of any Indian state. To better serve the healthcare needs of
this region, the Amrita Institute of Medical Sciences and Research Centre (AIMS) was established in
1997 in Kerala’s coastal city of Cochin. 
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Ron Gottsegen, 
Administrative Director of
AIMS 
“Our major concerns were
equipment reliability, the
manufacturer’s commitment
to continuing research and
development and its
willingness to invest its
personal efforts and
resources into our center to
make us successful and keep
us at the technical edge
where we wanted to be as a
teaching institute.” 
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enabling clinicians to treat about
five patients per hour. Two to
three hours each day are reserved
for new patient starts, which
average 45 minutes per slot. By
October 2004, with both Precise
Treatment SystemsTM operational,
the combined patient volume had
climbed to nearly 80 patients per
day. At press time, daily volume
is expected to be at maximum for
both systems for a combined
daily total of about 100
treatments. 
“With the high dose rate (up
to 600 MU/minute) of Precise
Treatment SystemsTM we have had
no problems treating our large
daily volumes,” Dr. Pillai says.
“In addition, field sequencing
enables us to very efficiently
deliver beams once we have
communicated the patient plan to
Desktop. And, with the built-in
record-and-verify system – which
is standard with Elekta – we have
not had any machine set-up
errors in treatments.”
70% of AIMS’s treatments are
3D conformal and employ wedge
and electron fields for
approximately 30% of all
patients. The case load comprises
36% head-and-neck cases, 20%
breast cancer and the remainder
a variety of other disease sites.
Maintaining this brisk depart-
ment workflow wasn’t simply a
matter of acquiring advanced
linacs, Dr. Pillai notes. Many
technologists in the area were
accustomed to outdated
equipment and needed intense
training and retraining, which
Elekta helped provide. “The
Elekta applications group did a
wonderful job of training
technologists, many of whom
were not only novices, but those
who had mostly used cobalt
machines and therefore had to un-
learn some of the techniques,” he
says. “The benefit of this training
was that we were able to get a few
trained technologists to serve as
anchors on both the machines.”
Further supporting AIMS’s
mission, Elekta offered to keep
two service engineers on-site to
perform all the first-line
maintenance and trouble-
shooting. “The down-time is
virtually always scheduled down-
time and it is working extremely
well,” Dr. Pillai says.
“We haven’t yet had a full day
of down-time on these systems,”
adds Dr. T.K. Padmanabhan,
M.D., Head of the Department
of Radiation Oncology, who
joined AIMS in January 2004
after working as a senior
consultant in Apollo Hospital,
Chennai for 11 years with two
non-Elekta linacs. “Our up-time
has been 98%, so I’m extremely
happy with the equipment.”
The new Elekta radiation
treatment systems at AIMS have
begun to relieve much of the
pressing load of cancer cases in
the over-burdened state of
Kerala, initiating a new era of
treatment availability among the
“We were impressed by the company’s growth, its technical innovation and capacity to move
products to market, and reports of equipment reliability. Elekta’s commitment was evident up and
down the line.”
energies, as I was used to just
two.” he says. “But when I
learned that Elekta offered three
photon energies, and appreciated
that southern India has a high
incidence of head-and-neck
cancers, I felt that 4MV would
be a very appropriate third beam
for AIMS to have. Plus, 4MV
would provide a very good
picture for Elekta’s iViewGTTM
portal imager.”
iViewGTTM itself was unique
among the other vendors’ portal
imaging devices, Dr. Pillai adds.
“Portal imaging and particularly
portal imaging with amorphous
silicon detection technology was
still in its infancy in 2000.
Although iViewGTTM was new to
clinical use, the images I believed
it could provide us would be
extremely useful.”
Beyond technical
considerations, the most
important factor favoring Elekta
was the level of commitment
Elekta showed during the
process. Elekta wanted a new
clinical partner in India and
clearly demonstrated this desire.
“Elekta invited us to its
facility in Crawley, UK, and
showed us how intently they
wanted to help us develop our
site,” he says. “Elekta struck us
as a progressive company that is
committed to creating a long-
term partnership and devoted to
the customer’s preferences and
satisfaction. We had to go
through the other vendors’
corporate layers, so in the end it
was as much a gut feeling for
Elekta as it was appreciation of
the technology.”
“Our major concerns were
equipment reliability, the
manufacturer’s commitment to
continuing research and
development and its willingness
to invest their personal efforts
and resources into our center to
make us successful and keep us
at the technical edge where we
wanted to be as a teaching
institute,” says Ron Gottsegen.
“Elekta scored very high in all
these areas. We were impressed
by the company’s growth, its
technical innovation and capacity
to move products to market, and
reports of equipment reliability.
Elekta’s commitment was evident
up and down the line, from the
corporate office to the Elekta
people in India. Elekta has done
everything, and continues to do
everything, necessary to make us
as successful as we are.”
In May 2002, AIMS placed
orders for two Precise Treatment
SystemsTM. The first system was
installed in the newly completed
AIMS Radiation Oncology
Department and accepted in
November 2003. Patient
treatments began on February
16, 2004. The second Precise
Treatment SystemTM was
delivered in April 2004, installed
and accepted in June 2004 and
started treating patients on
September 20, 2004. The CMS
XiO system is used for planning.
Volume builds quickly
By the end of its first week of
operation, Amrita’s first Precise
Treatment SystemTM was treating
20 patients per day, increasing to
50 patients by the end of May
2004. Demand for radiation
therapy services created a
backlog of about 30 patients,
despite initial clinic hours of  
7 a.m. to 9 p.m. The average
time slot was 12 minutes,
Pictured right: 
Meeting at the Elekta exhibit at ASTRO 2004
are (left to right); Percy Schroff, Managing
Director, Elekta India; Brendan Vahey, Director,
Sales & Marketing, Asia Pacific; Bhaskaran
Pillai, Ph.D., AIMS Chief Medical Physicist;
Volker Stieber, President & CEO, Elekta, UK
and Somnath Ray, National Manager, Product
Division, Elekta India. 
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state’s 32 million inhabitants, Dr.
Padmanabhan adds. 
“The only other cancer center
true to this designation is the
regional government-funded
cancer center in Trivandrum,
where most patients receive free
treatment and which has an
extremely heavy workload,” he
says. “Amrita Institute is a huge
leap forward in terms of
technology – not only in the state
of Kerala, but also in the entire
country, so this institution’s
Precise Treatment SystemTM really
improves the treatment outlook
for millions of people. Apart
from the Regional Cancer Centre
in Trivandrum, AIMS hospital
will have a major role in the
management of cancer patients in
Kerala.” 
“Elekta established a regional
office in Cochin before the
equipment installation and has a
team of engineers throughout the
country,” says Percy Shroff,
Managing Director of Elekta
India. “Our mission is to have
the most competent service
organization in India to provide
excellent after-sales support to
our customers in the country and
the region.”
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Mata Amritanandamayi, or ‘Amma,’ as
she is widely known in India and
worldwide, was the driving force in
AIMS’s establishment. During the last
30 years, the 51-year-old spiritual
leader has dedicated her life to
uplifting humanity through the
simplest of gestures – the embrace. In
this way, Amma has blessed and
consoled more than 21 million people
around the world. She has initiated
and inspired a vast network of
charitable activities, harnessing her
ability to transform her
compassionate vision into practical
reality. AIMS is the physical
manifestation of Amma’s vision to
create a hospital in Kerala where the
poor could receive the very best
medical care possible from highly
skilled physicians and nurses in a
compassionate, caring atmosphere.
“Amma’s message is one of love
and compassion,” says Prem Nair,
M.D., AIMS Medical Director. “There is
a strong bond that develops between
her and the people who meet her. It’s
the personal transformation that
occurs which allows people to work
selflessly toward a higher cause.”
According to AIMS Chief Medical
Physicist, Dr. Bhaskaran Pillai, AIMS
fulfills Amma’s creed of service to
fellow man in the area of medicine.
“This is a unique institution that is
one-of-a-kind in India and possibly
the whole world. AIMS’s first thrust is
to provide an opportunity for service
to humanity,” he says. “Secondly, its
goal is to provide these healthcare
services to the needy and provide
them at state-of-the-art level. A third
of our patients are treated for free,
another third is charged at
concessional rates and the last third
of patients is charged well below the
prevailing rates of other corporate
hospitals. Accordingly, after AIMS was
established many of the area
hospitals were compelled to reduce
their charges to the ultimate benefit
of all patients.”
The funds collected to create AIMS
and to finance countless other
charitable projects of Amma were
non-solicited donations and not
acquired through any fundraising at
all on Amma’s part, which testifies to
the spiritual leader’s ability to awaken
the spirit of giving among all whom
she encounters, Dr. Pillai adds.
“Private donations come not just from
a few individuals, but millions – and
yet not a single dollar is solicited. In
fact, Amma has instructed us to never
request funds. It’s her inspiration that
enables people to give selflessly.”
In relief of the victims of the
December 26, 2004 tsunami, Amma
has pledged a donation of Rs. 100
crores (US $22 million) and has
provided medical aid from AIMS as
well as aid in rebuilding homes for
the poor.
Amma, the ‘Hugging Saint of India,’
drives development of AIMS through
message of love
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“Our up-time has been 98%,
so I’m extremely happy with
the equipment.”
In the early 1990s, radiation
oncologist Vidya Bobba’s vision
was to create a cancer treatment
center that was as unlike the
standard example as possible – at
least from appearances. 
Dr. Bobba’s own ideas, and those
obtained through patient
questionnaires, resulted in a free-
standing outpatient treatment
center that looks like a home
from the outside with a warm,
inviting and decidedly non-
clinical feel inside. However, the
technological capabilities at
Redding Cancer Treatment
Center (RCTC), Redding,
California, USA are anything but
quaint. Through the years, 
Dr. Bobba has been quietly
building an arsenal of advanced
cancer-fighting technology.
Redding’s most recent acquisition
includes a Precise Treatment
SystemTM with iViewGTTM and
PreciseBEAMTM IMRT, which
executes IMRT plans developed
on the NOMOS CORVUS
planning system. 
Vidya Bobba, M.D., Radiation
Oncologist and founder of
RCTC, didn’t want to evoke
‘hospital’ among patients visiting
his site. While hospitals are
places where sick people go for
treatment, patients and visitors
often perceive the architecture,
ambience, décor and even sterile
smells as negatives. 
“The goal was to make the
center as unlike a hospital as
possible,” Dr. Bobba recalls.
“I’ve worked and trained in
several hospitals and their
drabness can be very
discouraging for patients. So, I
had the center built to look like a
house. On the inside we chose
colors, pictures and furnishings
that would put patients and
family members at ease.
Interestingly, we did not put in
things such as an aquarium or
provide jigsaw puzzles to help
Redding Cancer
Treatment Center 
builds disease-fighting
capabilities while
retaining non-clinical
ambience
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patients pass time, because we
wanted them in and out quickly
for their convenience.”
Since its opening in 1994,
RCTC has been very popular
with patients, he says. “They
really love it, and remark on how
nice it looks and how pleased
and comfortable they feel in this
place.” 
Practice grows steadily 
Starting with an Elekta SL18
treatment system  (upgraded to
an SL19) and SLS9 simulator,
and himself as the sole radiation
oncologist, Dr. Bobba began
treating patients from Redding’s
population of 85,000. Most
patients still come from Redding
today, but within a 15-mile
radius are approximately
150,000 residents, increasing to
350,000 inhabitants in the
greater region. “That doesn’t
sound like a lot, but there are a
lot of retired folks that tilt the
population for our specialty quite
a bit,” he says.
RCTC’s principal indications
have always been lung and breast
cancer, but prostate cancer
patients began flooding in over
the last three years when Dr.
Bobba and his associate Wayne
Koll, M.D., who joined the
practice in 1999, began
conducting real-time ultrasound-
guided brachytherapy
implantations. “We’re the only
center that does this in co-
operation with the urologists in
the community,” he says. “So,
now we see nearly 100% of the
prostate patients in Redding.”
Today, half of RCTC’s prostate
patients receive real-time
brachytherapy, while the other
half is treated exclusively with
external beam radiation therapy.
Approximately one third of the
seed implantations also receive a
five-week course of external
beam radiation therapy to treat
the prostate, seminal vesicles and
adjacent lymph nodes. At any
one time, eight prostate cancer
patients are on the treatment
schedule. For all indications,
RCTC treats approximately 40
patients a day.
Soon after the inception of the
brachytherapy program, the
treatment center continued to
improve its cancer treatment
services for prostate and head-
and-neck cancers with the 2001
acquisition of the NOMOS
Peacock MIMiC (highly
conformal MLC) system with
NOMOS Corvus IMRT software.
RCTC also acquired the
NOMOS BAT ultrasound system
for localization of the prostate. 
Precise Treatment SystemTM is
newest technology centerpiece 
in Redding 
Although RCTC inaugurated its
treatment services with Elekta
treatment and simulation equip-
ment, acquiring additional
radiation therapy equipment to
meet Redding’s burgeoning
demand wouldn’t be driven by
sentimentality for its first system. 
“In 2002, we re-did the whole
process of evaluation, and invited
both Varian and Elekta to make
sales presentations,” Dr. Bobba
says. 
In the end, several key
advantages convinced Dr. Bobba,
Dr. Koll, Chief Radiation
Oncology Physicist, Steven
Wallace, Ph.D (hired in 2002),
the dosimetrist and radiation
therapists that Precise Treatment
SystemTM would be the right
choice.
“The therapists and the
dosimetrist really liked the
operator-friendliness of the
existing Elekta system,” he says.
“Actually, when I evaluated that
system in 1993, I interviewed
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many therapists in various Elekta
centers and they unanimously
expressed their enthusiasm for
the user interface. We researched
portal imaging and realized after
evaluating several EPIDs that
iViewGTTM was the best on the
market, and indeed, the only
amorphous silicon detector. The
image quality is excellent.”
“I was very impressed with
iViewGTTM and continue to be,”
Dr. Wallace observes. “The
EPID’s superb image quality is
the reason we were able to start
using gold markers for daily
prostate localization. The
iViewGTTM software makes it
extraordinarily easy to calculate
the shifts patients need to make
in order to correct set-up errors.
The therapists can implement the
shifts very quickly and that was a
big plus for us.”
Perhaps the most important
deal-maker was Elekta’s promise
to assign a senior service engineer
to RCTC if they purchased
Precise Treatment SystemTM.
“Before we installed our second
Elekta system, Tom Belcham
became our service engineer,” he
says. “We really liked him and
told Elekta we would purchase
Precise Treatment SystemTM if the
company could convince him to
move to Northern California
from Los Angeles. Since then, he
has done a wonderful job.”
In May 2003, RCTC
completed acceptance testing on
Precise Treatment SystemTM,
equipped with MLCi, iViewGTTM
and PreciseBEAM® IMRT. In July
2003, commissioning was
completed and the system began
treating patients. Concurrent
with the Precise Treatment
SystemTM purchase, RCTC also
acquired a GE CT-simulator. 
RCTC is first to use NOMOS Corvus
IMRT software with MLC-equipped
Elekta system 
In the summer of 2003, Redding
continued its technology
acquisitions with the purchase of
the NOMOS Corvus IMRT
package for Precise Treatment
SystemTM. Integration of Corvus
with Precise Treatment SystemTM
would mark the very first MLCi-
equipped Elekta treatment system
to have this IMRT software. This
wasn’t just by chance; RCTC’s
Physicist, Dr. Wallace, worked
for a year at NOMOS focusing
on IMRT commissioning and QA
on a number of vendors’ MLC
modules, including Elekta’s. 
“In 2002, I began working at
RCTC, which less than a year
later would have Precise
Treatment SystemTM with MLC,
just as NOMOS was releasing
the new Corvus version, so the
cards just fell into place,” Dr.
Wallace recalls.
Around the time clinicians
began using Precise Treatment
SystemTM to treat patients in July
2003, Dr. Wallace began the
commissioning process for
Corvus. “We did a fairly
substantial QA procedure,” he
says. “For our first 10 patients, I
did film dosimetry in axial,
sagittal and coronal planes –
which is far above requirements,
but since this was the first one
we really wanted to make sure
the QA was comprehensive. We
then did a very thorough
individual patient QA, delivering
each plan four times, one to an
ion chamber and then to three
orthogonal films, before we put
the patient on the couch.”
In October 2003, RCTC began
Images of gold seed markers, front and
lateral views from iViewGTTM, both
simulation (top) and portal images
Vidya Bobba, (fourth from left, back row),
M.D., Radiation Oncologist and founder of RCTC
“The goal was to make the center as unlike a hospital as possible,” 
Dr. Bobba recalls. “I’ve worked and trained in several hospitals and
their drabness can be very discouraging for patients. So, I had the
center built to look like a house.”
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its prostate IMRT program on
Precise Treatment SystemTM. The
typical case specifies a 5-field,
75-segment treatment in a 
15-minute time slot. 
“Precise Treatment SystemTM
delivers 600MUs per minute,
which is a very fast dose rate, but
since we’re using a step-and-
shoot technique I was concerned
about our dose accuracy and
flatness and symmetry for small
MU segments,” Dr. Wallace says.
“I tested it with the ProfilerTM
and the ion chamber
measurements all the way down
to 1MU and it was very
acceptable, with dose accuracy
within 1% and flatness and
symmetry within 2%. And this
was for just a 1 or 2MU beam. I
was astonished with that.”
In addition to prostate IMRT,
RCTC also conducts IMRT for
head-and-neck cancer, and upper
abdominal and pelvic
malignancies.
Upgrades, acquisitions continue
to better serve community
In November 2004, RCTC
received the new Desktop ProTM
control system for Precise
Treatment SystemTM, which Dr.
Wallace predicts will shave five
minutes from IMRT delivery
times. “Beam loading will then
be virtually instantaneous, so we
will gain almost a minute per
field,” he says.
In addition, at press time, the
treatment center was upgrading the
SL18’s control system to Desktop,
Dr. Bobba says. 
“Presently, we’re also just
about ready to start HDR
brachytherapy with the Gamma-
Med Plus, and we’re going to
start doing MammoSite breast
implants,” he adds. “Our hope is
that – just like with prostate –
technology will attract and
benefit many breast cancer
patients.”
Since its founding in 1994,
RCTC’s staff has grown
dramatically as well. Mahesh
Pant, M.D., joined the center in
August 2004 and now the staff
includes three physicians, two
physicists, a dosimetrist, five
therapists, an administrator, a
medical assistant and two
administrative assistants. 
“The whole story of Redding
Cancer Treatment Center is one
of growth,” Dr. Bobba continues.
“The community is growing, the
population that will need our
services is also growing fast. So,
we’ll continue to acquire the
latest technology to meet the
needs of the residents of Redding
and this region.”
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Princess Margaret Hospital uses
Elekta Synergy® Platform with
XVI, in first ‘solo’ case of prostate
cancer patient
On September 29, 2004, Princess Margaret Hospital (PMH), Toronto,
Ontario, Canada became the second of four Elekta Synergy®
Platform with XVI, clinical installations to use 4D AdaptiveTM IGRT
VolumeViewTM. 
The volumetric (cone beam) scanning capability was used to
localize patient anatomy, with the patient in the treatment
position just before treatment. The prostate case occurred several
months after PMH researchers initiated an investigation comparing
Elekta Synergy® Platform XVI soft tissue matching with PMH’s
benchmark seed matching program for prostate cancer. 
PMH will conduct similar XVI treatments in additional patients who
are contraindicated for fiducial marker implantation, and intends
to expand clinical applications as work progresses. 
I M A G E  G U I D E D  R A D I A T I O N  T H E R A P Y
Charles Catton, M.D., Radiation
Oncologist, Princess Margaret
Hospital, a member of the Elekta
Synergy® Research Group
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100. The results showed that, in
general, both XVI and seed
matching techniques achieved
similar accuracy, with MV seed
matching and kV seed matching
being virtually equivalent.
“Using the cone beam to match
seeds versus the portal imager to
match seeds, there is very little
difference,” he reports. “From left
to right (L/R), there’s a 0.7mm
spread, from front to back (A/P), a
1.5mm spread and from top to
bottom (S/I), a 1.1mm spread.”
There was a slightly larger
divergence when comparing MV
seed matching with soft-tissue
matching. In this case the results
were: L/R, A/P, S/I = 1.0mm,
2.5mm and 2.3mm, respectively. 
A statistical comparison (R-
coefficient) yielded good to
excellent agreement between the
two techniques. MV and kV seed
matching showed high correlations
(R2 = 0.98, 0.95, 0.89 [L/R, S/I,
A/P]). There were lower, but still
good, correlations for shifts based
on soft tissue targeting (R2 = 0.97,
0.73, 0.71 [L/R, S/I, A/P]). 
Interobserver variability tested
real-world conditions, in which
different individuals would be
evaluating images (see below).
Interobserver variability:
MV seed matching vs. soft-tissue
matching (contoured CTV)
(mm) L/R A/P S/I
MV Seeds 0.3 0.9 0.5
Soft tissue 1.1 2.8 3.0
Average SD for 5 observers over 5
patients
“In MV versus kV seed
matching, different observers
agreed virtually all the time, to
within a millimeter,” Dr. Catton
notes. “With soft tissue, it’s not
quite as good, but still pretty
acceptable. The top/bottom plane
seems to be the most difficult to
deal with.”
Although at press time, PMH
had analyzed only a portion of the
acquired VolumeViewTM images,
Dr. Catton expects no surprises.
“The XVI images we acquired
were excellent and were all
perfectly useable for the purposes
of the study,” he says. “The two
matching techniques are not
identical, but they are comparable.
One possible reason that seed and
soft tissue matching on
reconstructions in the coronal and
sagittal planes are not identical is
because of the learning curve to
address. We have analyzed only
100 images so far, and it likely
took the therapists about 30
images to become accustomed to
the soft tissue matching process.
Secondly, the image quality isn’t
identical in all three planes – it’s
best in the axial plane, and you
can’t see the edge of the prostate
quite as well in the coronal and
sagittal planes.”
Next steps 
The next logical evolution of
PMH’s new soft tissue matching
technique is to implement the
technique in real-time. 
“Once we limit the therapist to
20 minutes to do the match, their
challenge will be to acquire the
images, do the match and treat the
patient while still maintaining the
same level of accuracy that they
achieved when working quietly in
the evening, and I think we are
very likely to achieve that with this
system,” he says.
W A V E L E N G T H  |  V O L  9 .  N O . 1  |  M A R C H  2 0 0 5 W A V E L E N G T H  |  V O L  9 .  N O . 1  |  M A R C H  2 0 0 51 2 1 3
C
A
S
E
 S
T
U
D
Y
Since 1997, PMH clinicians have
refined a strategy to address
prostate motion in an effort to
improve the radiation therapy
accuracy. PMH’s benchmark
technique uses fiducial markers
implanted in the prostate for target
localization and to serve as
reference points to improve the
accuracy of MR image fusion. 
“The use of implanted gold
markers is a robust method that
enables daily on-line imaging of
the target, but it does have
disadvantages,” according to
Charles Catton, M.D., Radiation
Oncologist at PMH. “It is invasive,
adds time to the planning process
and requires an expert
inverventionalist to implant the
seeds. The markers can also
degrade planning CT images and
this method can only be used on-
line with an amorphous-silicon
imager.”
An ongoing study that began in
February 2004 comparing PMH’s
seed matching technique and soft
tissue matching using Elekta
Synergy Platform® XVI
demonstrated that the two image
matching techniques yield
comparable accuracy. Accordingly,
on September 29, 2004, PMH
conducted its first Elekta Synergy®
Platform treatment unaided by
portal imaging in a patient for
which seed implantation was
contraindicated.
“We’re flying solo with this
gentleman,” Dr. Catton says. “In
other words, we’re using Elekta
Synergy® Platform’s XVI
volumetric kV imaging capability
(VolumeViewTM) as the sole
technique for image matching. He’s
halfway through his 42 fractions
and it’s going great.”
Study demonstrates
excellent image quality 
with XVI
Because PMH’s study population
was comprised entirely of patients
with previously implanted fiducial
markers, investigators had to first
address issues of image degrada-
tion and observer bias, Dr. Catton
says.
“The gold seeds right in the
middle of the prostate were
interfering with the kV image
quality and also causing observers
to inadvertently focus on the seeds
rather than on the soft tissue,” he
observes. “To deal with these
issues for the purposes of our
study, our physicist devised a
program to electronically delete the
seeds from the images.”
Over the next few months,
clinicians acquired – and stored for
future analysis – a volumetric data
set of each patient before
proceeding with the customary
seed matching protocol using
Elekta iViewGTTM electronic portal
imager.  Any necessary adjustments
were made to the patient’s set-up
before treatment. Later in the
evening, the therapist would pull
up the VolumeViewTM images and
perform two retrospective matches.
“They matched MV seed
matching versus kV seed matching,
then erased the seeds and
compared MV seed matching to
soft tissue matching,” Dr. Catton
explains. “This latter match was
done by moving the cone beam
image to match the target as
closely as possible to determine the
degree of agreement with seed
matching.”
At press time, of the 600
VolumeViewTM images acquired,
PMH researchers had analyzed
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“We conducted an exhaustive
search of linear accelerator
vendors specifically looking for
IGRT capability, and based on
that search criterion we chose
Elekta,” says Todd Barnett,
M.D., Radiation Oncologist and
Medical Director at the Swedish
Cancer Institute, the largest
cancer treatment provider in the
Northwest USA. “In the end we
really sensed that Elekta is ahead
of the curve technologically and
that Elekta Synergy® is actually
treating patients clinically. Addi-
tionally, we very much wanted a
strong partner to team up with
us on research, and we believed
Elekta also strongly valued such
a relationship.”
Another key differentiator, 
Dr. Barnett points out, is that all
Elekta products, including Elekta 
Synergy®, are networkable with
the treatment planning and
record-and-verify products of
multiple vendors. “Swedish
Medical Center is a large
complex network that has
invested significantly in many
vendors’ products,” he says.
“Going with our current vendor
for IGRT would have compelled
us to use most of its ancillary
products as well, which would
have been a lengthy, complex and
expensive project.”
Lung cancer program to benefit
with Elekta Synergy®
Elekta Synergy® system’s ability
to image patients at the point of
treatment will profit the Swedish
Medical Center’s lung cancer
program, Dr. Barnett observes.
“We don’t know what’s
happening in these lung cancer
patients, in terms of both inter-
and intrafraction target motion,”
he says. “Consequently, we’re
reluctant to make our margins
much tighter due to this
uncertainty. Elekta will be
working with us to develop a
protocol and image registration
tools for Elekta Synergy® that
should improve these treatments
and give us greater clinical
confidence.”
Elekta Synergy® S will complete
stereotactic center of excellence 
With the later addition of Elekta
Synergy® S, Swedish Medical
Center will have the tools
necessary to become a stereotactic
center of excellence – Elekta
Synergy® S for extracranial
radiosurgery and Leksell Gamma
Knife® for intracranial radio-
surgery.
“Our medical oncologists and
surgeons want better treatment
options for patients with liver
metastases, paraspinal metastases
and even pancreatic primary
tumors – targets where surround-
ing structures are very sensitive,
and where we could perform
some highly focused treatments.”
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Swedish Medical Center to
acquire Elekta Synergy® and
Elekta Synergy® S systems
The first of three Elekta Synergy®
systems will arrive at the Swedish
Cancer Institute (part of the
Swedish Medical Center, Seattle,
Washington, USA) in early 2005.
Two additional Elekta Synergy®
systems and an Elekta Synergy® S
will be installed in the third and
fourth quarters of next year. The
Elekta acquisitions represent
Swedish Medical Center officials’
realization that Elekta is capable –
today – of supplying the image-
guided radiation therapy (IGRT)
equipment the center would need
to enter a new phase of advanced
radiation therapy.
I M A G E  G U I D E D  R A D I A T I O N  T H E R A P Y S T E R E O T A C T I C  R A D I A T I O N  T H E R A P Y
N
E
W
 IN
S
T
A
L
L
A
T
IO
N Elekta and Royal Preston Hospital 
team up to fine tune the physics and clinical aspects 
of the  Beam ModulatorTM
Medical equipment manufacturers always get the most useful assessments of a new product when the device has spent
time operating in the real-world laboratory of the clinic or hospital. These assessments are even more valuable when
obtained before the product is commercially introduced. In 2003, Elekta had the opportunity to test the pre-market version
of Beam ModulatorTM (Elekta’s fine resolution beam-shaping system) at the Royal Preston Hospital (RPH), Rosemere Cancer
Centre, Preston, Northern England, in collaboration with an Elekta team. The project resulted in many improvements that
are now integrated in the commercial Beam ModulatorTM, a key component of Elekta Synergy® S, Elekta’s platform for
advanced stereotactic radiation therapy.
In the spring of 2003, RPH was
in negotations for a sixth linear
accelerator, one equipped with a
fine-leaf MLC capable of
stereotactic treatments. Elekta
was among the finalists in the
evaluation, although Elekta’s
Beam ModulatorTM – the beam-
shaping component of Elekta
Synergy® S – was still in pre-
verification development. 
“We wanted an integrated
MLC, not an add-on device,”
says Dr. Michael Kirby,
Consultant Physicist, Deputy
Head of Radiotherapy Physics at
RPH. “Plus, we have a long
history with Elekta. All our linacs
and simulators are from Elekta
and it was desirable to maintain
our good working relationship.
Although we didn’t know then
that we would be the Beam
ModulatorTM test site, there still
was the attraction of being
among the first centers globally
to have this new technology.
Royal Preston has always prided
itself on using novel technology
to its fullest and on being at the
forefront of routine use of, state-
of-the-art radiation therapy
delivery for as many patients as
possible. Selecting Beam
ModulatorTM was a way of being
at the forefront with a new
product and evaluating it in a
clinical environment.”
Royal Preston Hospital
agrees to testing
partnership
What would change the
complexion of this Beam
ModuatorTM acquisition,
ironically, was a resource issue,
Dr. Kirby says. “Royal Preston
didn’t have enough radiographers
to operate its complement of
linacs, thus leaving one treatment
machine underutilized.” At
Elekta, meanwhile, Beam
ModulatorTM was undergoing
extensive engineering. In April
2003, Elekta took a prototype
Beam ModulatorTM to Brighton
and Sussex University Hospitals
to re-evaluate the penumbra
following leaf tip modifications
using the center’s non-
commissioned linac. Because
further testing was desirable on a
clinical machine, Elekta issued a
field request to locate a clinical
site capable of conducting these
tests. In May 2003, Paddy
Greally, the Elekta representative
for RPH, notified headquarters
that the Elekta SL15 at RPH
could be modified to incorporate
Beam ModulatorTM for testing. 
“Paddy told us we would have
a shelter available from June
until at least September,” says
Beam ModulatorTM Project
Manager, Mark Knowles. “It was
like gold – we jumped at the
chance. We know from vast
experience that when we go to a
hospital, especially with a new
MLC during pre-verification –
when the door is open to accept
design changes and
improvements – we can improve
the product.”
On June 17, 2003, a meeting
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between Elekta and RPH
representatives generated a
proposal for a ‘testing in partner-
ship’ venture. The agreement
covered installation of the pilot
Beam ModulatorTM hardware and
software, upgrade to Desktop
ProTM, set-to-work and
calibration. Additionally, the
project specified a comprehensive
range of tests, including physics
data collection, safety and
performance, clinical workflows
from planning to treatment
delivery, and verification test case
dry runs. 
“It was truly a collaborative
venture. The project involved
engineering, clinical and physics
staff from both Elekta and the
Royal Preston,” Dr. Kirby notes.
“Elekta staff installed the
Desktop ProTM upgrade and did
data collection, set up the
connection between Precise-
PLAN® and Beam ModulatorTM
and tested the optics.
Concurrently, Preston staff
evaluated the technical ability of
Beam ModulatorTM, examining
leakage characteristics, leaf
position accuracy and
reproducibility, stability of Beam
ModulatorTM optical assembly
and MLC camera image, leaf
penumbra, connectivity to a
commercial TPS, improvements
in isodose shaping and
distributions and analyzed its
ability to deliver IMRT.
Ultimately, a joint team of Elekta
and Preston clinical staff, led by
Superintendent Radiographer
Helen Clements, evaluated actual
clinical delivery and workflow
aspects by running through a
number of test cases.”
The Beam ModulatorTM and
Desktop ProTM upgrades to RPH’s
SL linear accelerator, and
calibration and set-to-work
activities occurred in August and
September 2003, followed by the
start of the main test period in
September.
Testing reveals
sophistication
of Beam ModulatorTM
The RPH-Elekta team discovered
some key areas in which Beam
ModulatorTM could be improved,
and was pleased with the
integrity of the device.
“Our overall impression was
that technically everything looked
very good,” Dr. Kirby recalls. “We
were perfectly happy with beam
outputs, wedge factors, leaf
positioning reproducibility and
stability and how Beam
ModulatorTM was set up. We were
even able to deliver an IMRT plan
(on a phantom) in the first week.” 
On December 2, 2003, the
RPH team presented its Beam
ModulatorTM test results to all
Elekta users in Northwestern
England. With their Elekta
colleagues present, RPH
representatives discussed engi-
neering, radiation therapy
physics, clinical workflow and
IMRT verification aspects, and
gave Elekta clinical users a
hands-on tour of the testing
configuration.
“We wanted other customers
to witness the benefits of Beam
ModulatorTM in a clinical setting
and hear about them from
clinical professionals,” Dr. Kirby
says. Numerous other
presentations by RPH staff
followed including; 
– February 2004, internal
seminars at Elekta, Crawley,
UK
– June 2004, presentation as
part of Elekta’s ‘A clinical and
product review for UK Elekta
customers,’ Crawley, UK
– September 2004, presentation
at the IPEM ASM, University
of York, York, UK 
– October 2004, poster
presentation at ESTRO,
Amsterdam, the Netherlands.
As a result of RPH’s successful
verification testing of Beam
ModulatorTM, Elekta asked the
hospital to help conduct formal
validation of the technology
beginning in March 2004. RPH
also performed IEC 60976 testing
from July to September 2004.
This improved version of Beam
ModulatorTM was installed on one
of RPH’s newest Elekta linacs in
December 2004.
“Validation went exactly
according to schedule, because
we had ironed out virtually all
technical issues,” Knowles adds.
Testing in partnership
benefits all parties 
RPH professionals take great
pride not only in using advanced
technology, but also in learning
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enough about it to provide
development input. Accordingly,
testing Beam ModulatorTM was a
very appealing prospect. 
“We were deeply interested in
knowing exactly what Beam
ModulatorTM could do and also
to be involved at a stage where
we could possibly influence its
development. To see that
feedback reflected in the final
clinical product is immensely
satisfying,” Dr. Kirby says. 
“The testing in partnership
venture with the Royal Preston
made Beam ModulatorTM what it
is today – a reliable, clinically
useable, installable safe
component, a component that
will enable Elekta Synergy® S to
satisfy the customer’s advanced
stereotactic needs,” Knowles
adds. “Plain and simple, if we
hadn’t gone to the Royal Preston
last autumn, Beam ModulatorTM
would not be as good as it is
today.”
In December 2004, RPH
began commissioning a
production Beam ModulatorTM
on its Elekta Synergy® Platform.
The system will be used to
evaluate the field shaping
capabilities of Beam
ModulatorTM.
“We will begin using Beam
ModulatorTM at the end of March
2005, focusing on prostate cases,
and in time, head-and-neck cases.
We believe we will obtain
extremely good field shaping for
prostate fields due to the finer
resolution. The planning studies
we did, led by Glyn Shentall,
Head of Radiotherapy Physics at
Rosemere showed dramatic
improvements in isodose shaping
for prostate and head-and-neck
targets,” Dr. Kirby notes. “We
will be doing further tests on
Beam ModulatorTM robustness
and reproducibility and data
collection. Other UK sites are
also acquiring Beam
ModulatorTM, and we are going
to keep open channels with them
so we can effectively commission
them in parallel.”
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With the 46th annual meeting
of the American Society of
Therapeutic Radiology and
Oncology (ASTRO, October,
Atlanta, Georgia, USA) as the
backdrop, Elekta continued to
assert itself as the undisputed
leader in image-guided
radiation therapy (IGRT) with
two major IGRT meetings: the
first meeting of the Elekta
Synergy® Research Group and
an IGRT educational
symposium, each of which
drew hundreds of attendees.
“These conferences staked out
Elekta’s clear leadership position
in 4D AdaptiveTM IGRT offered
by Elekta Synergy®, an image
guided robotic linear
accelerator,” says Rajinder Singh
Dhada, Director, Global
Marketing at Elekta. “These
meetings emphasized the
important role of IGRT in
providing the most effective
radiation therapy treatments and
that Elekta is at the forefront in
this field with a 4D AdaptiveTM
IGRT solution in clinics treating
patients today.”
The Elekta Synergy® Research
Group (the first global users
meeting of Elekta Synergy®
customers) was held October 2,
2004 at Atlanta’s Fox Theatre.
More than 100 customers, who
have purchased Elekta Synergy®,
Elekta Synergy® Platform and
Elekta Synergy® S, attended the
event, along with Elekta officials
and key members of the Elekta
Synergy® Research Group.
The Elekta educational
symposium on 4D AdaptiveTM
IGRT in the clinic convened on
October 2, 2004 at the 755 Club
at Turner Field, Home of the
Atlanta Braves. This meeting
attracted over 450 radiation
oncologists, physicists, therapists,
dosimetrists and administrators. 
Elekta Synergy® Research
Group emphasizes clinical
breakout of world’s first IGRT
system
To highlight the first global users
meeting of Elekta Synergy®
customers, talks were given by
representatives of the Elekta
Synergy® Research Group, the
founding members of which are:
William Beaumont Hospital
(WBH), Royal Oak, Michigan,
USA, the Netherlands Cancer
Institute (NKI/AvL), Amsterdam,
the Netherlands, Christie
Hospital (Christie), Manchester,
UK and Princess Margaret
Hospital (PMH), Toronto,
Ontario, Canada).
After confirming Elekta
Synergy® system’s ability to
acquire single volumetric images
with VolumeViewTM – to verify
treatment delivery in a wide
variety of disease sites – Christie
began acquiring multiple serial
images, according to Christie’s
Ann Henry, M.D. 
“We acquired VolumeViewTM
images of patients with bladder
cancer for the first five treatment
days, and then once weekly
during treatment,” she said. “The
coronal images were very good
for verification in 3D treatment
delivery to the CTV. In 93% of
the images, the CTV was within
the PTV and the GTV was
always within the PTV.”
Conferences confirm Elekta’s continuin g dominance in 4D AdaptiveTM IGRT 
Christie clinicians also
obtained promising results in
Elekta Synergy® lung tumor
studies 
“For several patients, we’re
acquiring AP and lateral Planar-
ViewTM kV static and Motion-
ViewTM fluoroscopic qulaity
images over two to three
breathing cycles and evaluating
systematic and random set-up
errors and lung tumor motion,”
she said. “The PlanarViewTM kV
static images give us much better
bony anatomy definition and soft
tissue resolution than electronic
portal imaging.”
Christie’s prostate studies
entail daily tracking of prostate
motion. Elekta Synergy® is used
for off-line analysis of CTV
coverage to correct for systematic
errors (translations). Investigators
are also conducting on-board
planning studies that employ
Elekta Synergy® VolumeViewTM
volumetric imaging to assess the
impact of deformation. 
Di Yan, Ph.D., WBH,
discussed ongoing projects in
Adaptive Radiation Therapy
(ART) utilizing Elekta Synergy®.
These include hypofractionation
of prostate cancer, accelerated
radiation therapy for lung cancer
and partial breast treatment.
“These treatment processes all
use Elekta Synergy® for either on-
line navigation to correct for
patient position and/or as an off-
line tool for adaptive planning
modification to account for the
patient’s temporal changes during
the treatment course,” Dr. Yan
said.
WBH’s applications afford the
opportunity to evaluate Elekta
Synergy® system’s various
imaging modes. For example,
Motion-ViewTM is used to
monitor breathing motion in lung
treatments. “We can generate a
digitally reconstructed image
from 4D adaptive planning that
is used to compare with portal
MotionViewTM before treatment
to verify how the breathing
pattern affects tumor motion and
make treatment corrections
accordingly,” he says. 
The concept is similar for
partial breast treatments, except
that implanted markers are
tracked. “There’s a surgical
marker around the tumor bed,”
Dr. Yan says. “When we treat the
patient, we use VolumeViewTM
and MotionViewTM to monitor
marker position, and determine
what kind of modification is
needed.”
Additional Elekta Synergy®
updates were given by Harry
Bartelink, M.D. (NKI/AvL) and
David Jaffray, Ph.D. (PMH).
Elekta Strategic Program
Manager, Elekta, Robert Pitt,
provided an update on Elekta’s
stereotactic body radiation
therapy IGRT program featuring
Elekta Synergy® S. 
Elekta Research Director,
Kevin Brown, shared his view
that the technical development
phase of Elekta Synergy® is
officially over. “We are at the end
of a period of significant product
engineering and moving into an
era of very broad clinical
deployment and development.”
He observed that the Elekta
Synergy® Research Consortium
will enable Elekta Synergy® users
to share best practices and will
serve as a clearing house for the
collection of clinical data that
will sustain funding and
reimbursement for 4D AdaptiveTM
IGRT. 
Jill Stief, Product Manager,
Imaging and Positioning, Elekta,
provided product update
information on Elekta Synergy®
and imaging software tools,
which detailed a number of new
software options and packages.
Most significant are software
options for three imaging modes:
MotionViewTM, PlanarViewTM and
VolumeViewTM. 
Symposium demonstrates
Elekta’s leadership position
in IGRT
Clinicians at the four Elekta
Synergy® Research Group insti-
tutions provided compelling
testimony on the practical imple-
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Synergy®) respiratory-correlated
scan, we have fairly good
visualization of the tumor
throughout the breathing cycle. A
respiratory curve can be used to
create a probability density
function for tumor motion, to
determine the mean position of
the tumor based on the breathing
cycle position.”
WBH’s 4D union technique
(GTV = union of all GTVs
acquired during 4D image
scans), incorporates respiratory
motion, enabling accurate
definition of tumor position over
time, Dr. Kestin notes. “Their
4D adaptive technique builds on
this concept, incorporating
further information, including
the probability density function
of tumor location, to reduce the
margin while still assuring
accurate coverage of the tumor
in all phases of the breathing
cycle.”
Laura Dawson, M.D. (PMH),
discussed the use of image
guidance in a stereotactic hypo-
fractionated radiation treatment
protocol for primary and
metastatic liver cancer. “When
feasible, patients are treated with
their liver immobilized using
Active Breathing CoordinatorTM.
Using daily orthogonal MV
portal imaging, PMH therapists
reposition the patient for any
offset in diaphragm position of
3mm or more.”
“This has enabled us to
improve the accuracy of set-up,
but MV orthogonal imaging has
limits,” Dr. Dawson observed.
“The image quality for bone is
not as good as that of kV, and
the process is based on 2D
alignment of vertebral bodies and
the diaphragm, which is a
surrogate for the liver.”
Using Elekta Synergy® Platform
with XVI, PMH acquired 53
orthogonal sequence mode
(MotionViewTM) sessions and 53
cone beam images in 15 patients
with liver cancer. “kV imaging of
fluoroscopic quality allows
confirmation of the liver position
and range of liver motion due to
breathing immediately before
each radiation fraction,” she said.
“We recently used Elekta
Synergy® with XVI to obtain
volumetric imaging of the liver,
immobilized using Active
Breathing CoordinatorTM. This
3D verification imaging is
providing us with far more
information than we had with
megavoltage imaging and we are
looking forward to using Elekta
Synergy® Platform with XVI for
image guidance of future liver
cancer patients.”
Additional presentations on
early experience with IGRT in
the clinic were given by Alvaro
Martinez, M.D. (WBH), Charles
Catton, M.D. (PMH, see article
page 11) and Marcel van Herk,
Ph.D. (NKI/AvL).
mentation of Elekta Synergy®
today, at the Elekta Educational
Symposium on 4D AdaptiveTM
IGRT in the Clinic. 
Christie’s Jonathan Sykes
discussed two possible future
applications of Elekta Synergy®,
Intensity Modulated Arc Therapy
(IMAT) and kV fluoroscopy. “In
IMAT, Elekta Synergy® could be
employed in an off-line adaptive
protocol for auditing patient
position during treatment,” he
said. “Performing the gantry
rotations for both imaging and
treatment simultaneously would
save time, but we would have to
determine how much MV scatter
is encountered at the kV panel.”
Utilizing a Farmer chamber,
Sykes measured MV scatter to be
0.14Gy/min. or less than 0.2% of
the dose at dmax. “MV scatter
deteriorates image quality in
terms of contrast-to-noise, but it
may be possible to improve
image quality by using scatter
reduction techniques,” he
observed. “The reconstruction
image quality is sufficient for
automated 3D registration of
high-contrast anatomical
interfaces, such as bone-tissue
and tissue-air interfaces.”
Sykes also discussed the
potential of Elekta Synergy®
using either or both kV and MV
imaging systems for real-time
tracking of tumor motion in the
upper abdomen and lung. “It
may be possible in some cases to
track the movement of features in
the image and use these to infer
tumor motion,” he said. “An
alternative is to track the motion
of radiographic markers
implanted in the tumor. Both
strategies focus on finding a way
to gate treatment based on tumor
position.”
“Challenges arise in real-time
measurement since both MV and
kV beams are needed; the tumor
may fall outside dose tolerance,
necessitating turning off the MV
beam and losing a key
measurement dimension,” he
said. “Similarly, if the MV beam
were an IMRT prescription, the
MLC would inevitably obscure
the marker of the feature being
tracked. Therefore, the future of
real-time measurement using
Elekta Synergy® would be for
validating indirect methods of
monitoring tumor motion, such
as tracking the surface of the
lung or validating using Active
Breathing CoordinatorTM.”
To test the effects of MV
scatter on contrast detail, Sykes
imaged a contrast detail test
object and gold seeds sandwiched
between two slabs of solid water,
with and without the MV scatter.
“MV scatter reduces the visibility
of all sizes of contrast detail,
which will make automatic
detection of small objects, such
as radiographic markers, more
difficult,” he explained.
“Solutions include either
increasing the exposure or
increasing marker size. A
promising alternative could be
using synchronous interlacing of
MV and kV exposures.”
Larry Kestin, MD (WBH),
discussed the difficulties in free-
breathing slice-based CT of lung
tumors and how Elekta Synergy®
was used to address these
challenges. 
“Unlike conventional CT,
respiratory-correlated cone beam
CT doesn’t require an external
signal – you can just use the
diaphragm from the images,” he
said. “As long as we know in
which breathing cycle phase each
projection was obtained, we can
reconstruct these images in a CT
data set in that position of the
breathing cycle. In the (Elekta
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TopKevin Brown, Elekta Research Director,
and David Jaffray, PhD., PMH, at the
seminal meeting of the Elekta Synergy®
Research Group, October 2nd, 2004
Bottom Marcel van Herk and Harry
Bartelink, M.D., NKI/AvL, presenting at
the Elekta Educational Symposium on 4D
AdaptiveTM IGRT, October 2nd, 2004
“The PlanarViewTM
kV static images give us
much better bony
anatomy definition and
soft tissue resolution than
electronic portal imaging.”
“In the (Elekta Synergy®)
respiratory-correlated
scan, we have fairly good
visualization of the tumor
throughout the breathing
cycle.” 
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n In the breast cancer area,
demonstrators showed how
Active Breathing CoordinatorTM
can help shield the heart from
radiation, while OmniWedgeTM
software creates virtual wedges
in any direction, that help obtain
greater dose conformality to the
treatment area. 
n The lung cancer area featured
Stereotactic Body Frame®, a tool
for enabling increased dose
delivery to the target in a
reduced number of fractions –
one clinic is ensuring high
conformality for lung tumors
using real-time MotionViewTM
during patient set-up on Elekta
Synergy®
n Elekta Synergy® VolumeViewTM
dramatically increases targeting
accuracy by enabling the
visualization of soft tissue shape
and position, according to one
clinic’s experience, as highlighted
in the prostate cancer area.
Another clinic uses
VolumeViewTM in an off-line
adaptive manner to measure
systematic errors, enabling PTV
reductions.
n Lastly, the metastatic disease
area highlighted the use of
Leksell Gamma Knife® 4C to treat
multiple brain metastases on an
out-patient basis. In addition,
one clinic is considering the use
of Elekta Synergy® to rapidly
image, verify and palliatively
treat a patient suffering pain
from a spinal metastasis. 
An estimated 10,000 radiation
oncology professionals attended
the 46th ASTRO in Atlanta,
Georgia, USA, October 3-7, 2004
at the Georgia World Congress
Center.
Elekta Synergy®, Elekta
Synergy® S and 4D AdaptiveTM
IGRT formed the centerpiece of
Elekta’s offering. Around this
unequaled IGRT portfolio, Elekta
also built a forceful case for its
continuing pre-eminence in
neurosurgery and radiation
oncology solutions with its broad
arsenal of disease-fighting
weapons, including Precise
Treatment SystemTM, Leksell
Gamma Knife® 4C, Precise-
PLAN®, PreciseBEAM® IMRT,
Stereotactic Body Frame®, and
Active Breathing CoordinatorTM. 
At ASTRO 2004, Elekta
presented IGRT, neurosurgery
and radiation oncology, under
the theme of “Disease-focused
Solutions,” clinical solutions that
physicians can harness to treat
breast, lung, prostate and
metastatic disease. Elekta’s
sophisticated stereotactic tools
and accurate disease targeting
technology become potent
weapons in the hands of
clinicians, giving them the power
to fight cancer more aggressively
than ever before without
endangering healthy tissue.
“Only Elekta gives clinicians
the power to treat their patients
with unmatched accuracy using
IGRT or disease-focused
solutions,” says Anthony De
Carolis, President and CEO of
Elekta North America, Inc.
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“Elekta remains at the forefront
of technology, business solutions
and treatment solutions. Our
commitment to research and
development, and to expanding
our solutions will continue to
fuel Elekta’s growth, as well as
the growth of centers using our
technologies.”
Elekta Synergy® still drawing
thousands
The ASTRO 2004 Elekta Synergy®
exhibit continued to attract intense
curiosity and attention, even a full
year since Elekta Synergy®, the
world’s first IGRT system, was
launched at ASTRO 2003.
Continuous Elekta Synergy®
demonstrations were given at the
Elekta exhibit during the five-day
meeting, attracting large audiences.
Attendees learned that Elekta
Synergy® systems in clinical sites
worldwide have acquired nearly
2,000 images among 200 patients
and across a broad spectrum of
clinical indications.
This year’s conference
highlighted new software
options; single image mode
(PlanarViewTM), sequence image
mode (MotionViewTM) and
volume mode (VolumeViewTM),
part of Elekta Synergy® X-ray
volume imaging technology. Also
at ASTRO 2004, a total of 15
presentations and 16 posters
featured Elekta 4D AdaptiveTM
IGRT,  adding to an Elekta IGRT
bibliography that currently lists
127 presentations and papers in
2004 alone.
Elekta Synergy® has made such
tremendous progress in the last
year that Elekta had the critical
mass of interest in the radiation
oncology community and wealth
of clinical experience within the
Elekta Synergy® Research Group
to host two IGRT meetings at
ASTRO 2004: the very first
meeting of the Elekta Synergy®
Consortium and an IGRT
educational symposium, each of
which drew hundreds of
attendees.
“In the arena of IGRT,
ASTRO 2004 was a stunning
success for Elekta,” says Rajinder
Singh Dhada, Director, Global
Marketing at Elekta. “Elekta
clearly demonstrated its
committment and the leadership
position with clinically working
4D AdaptiveTM IGRT solutions
that we can offer doctors today.
This was reflected in the
attention Elekta Synergy®
received at the exhibit, the
number of papers and posters on
Elekta 4D AdaptiveTM IGRT and
the incredible attendance at our
IGRT events.”
A weapon for all common 
clinical challenges
At the four corners of Elekta’s
ASTRO 2004 exhibit were
disease-based clinical solutions,
featuring sophisticated Elekta
stereotactic tools and disease-
targeting technologies. 
Backed by:
n Scientific papers
n The Elekta Synergy® consortium
n The Elekta IGRT educational
symposium
n A visitor-packed Elekta IGRT
demonstrations and 
n Ample evidence of Elekta 4D
AdaptiveTM IGRT in clinical
practice today
Elekta made a
powerful statement at
ASTRO 2004 that it
leads the world in
IGRT
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Elekta’s IGRT leadership on display 
at ASTRO 2004
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